PALM BEACH GARDENS, FL--(Marketwire - March 03, 2010) - AccuDial Pharmaceutical, Inc. announced today that their initial financing, a private placement for four million shares at $1 per share, has been successfully closed. This funding round was accomplished entirely by AccuDial's management team and board of directors without any institutional involvement.
On January 13, 2010, the company launched its family of pediatric, liquid weight-based dosing medications in Canada, with Walmart being the first retailer to offer AccuDial's eight analgesic, allergy, and cough and cold products. By April 2010, the company expects to be in 4,000 stores, and by September 2010, AccuDial projects it will have floor displays and products on the shelves in 6,013 grocery and drugstores across Canada. In addition, the AccuDial Web store is "OPEN FOR BUSINESS" for all Canadian parents and has both French and English-language Web pages. The company plans to launch its family of pediatric medications in the United States in Q4 2010, followed by Europe, Brazil, and Japan. All eight of AccuDial's products were approved in 2009 by the Canadian regulatory agency, and the company is in the process of completing regulatory filings with the FDA.
What differentiates AccuDial from all other over-the-counter pharmaceutical products, including Tylenol, Dimetapp, Triaminic, and generic store brands, is the company's patented rotating dosing label that enables caregivers to measure and dose their children based on weight and not age ranges. "All children the same age do not weigh the same," said Bob Terwilliger, CEO and president of AccuDial. "Physicians, pediatricians, pharmacists, and hospitals dose by weight, NOT age," he remarked.
Dr. James E. Heubi, M.D., Professor of Pediatrics and Director, General Clinical Research Center at Cincinnati Children's Hospital Medical Center, told AccuDial, "As a practicing pediatrician since 1979, our standard of care for prescribing all medications to children under the age of 12 has been and continues to be dosing by weight. The AccuDial line of children's over-the-counter medications embodies dosing by weight in a user-friendly way that promotes medication safety and effectiveness."
"All AccuDial medications are bioequivalent to products from Johnson & Johnson, Pfizer (formerly Wyeth), and Novartis," said Dr. Brian Kaplan, co-founder and chairman of AccuDial. "AccuDial is easy for mom to use -- even at three in the morning," Kaplan continued. "Mom rotates the label on the medicine bottle until her child's weight appears in a large viewing window. The weight and dose is displayed in the window and a cylindrical dosing spoon, which is properly calibrated, is included to easily administer the medication."
"AccuDial is a great value," observed Bob Terwilliger. "In these economically challenging
times, mom gets an easy-to-use medication with weight-based dosing information, great taste, and is comparable to other national brand products, plus an accurate dosing spoon for about $1 less than Tylenol, Dimetapp, and Triaminic."
About AccuDial Pharmaceutical:
AccuDial Pharmaceutical's patented, weight-based dosing was designed to effectively administer AccuDial's family of children's pain and fever, allergy, and cough and cold medications. A parent simply rotates the label until their child's weight appears in the viewing window and the correct dose is shown below the weight. A dosing spoon is included in each package so parents can easily measure and administer the medication. Children's AccuDial is the only medication that provides weight-specific dosing using a rotating label. For more information, contact AccuDial Pharmaceutical, Inc., 8409 North Military Trail, Palm Beach Gardens, FL 33410, www.accuratedose.com. To download photos for use with this press release, visit our Flickr account at http://flickr.com/gp/venuemarketing/H0AG5r.
The information contained in this press release includes "forward-looking statements." All statements other than statements of historical facts included in this press release, including the Company's prospects, plans, financial position, and business strategy, may constitute forward-looking statements. These statements are based on the beliefs and assumptions of our management and on the information currently available to our management at the time of such statements. Forward-looking statements generally can be identified by the words "believes," "projects," "expects," "anticipates," "intends," "plans," "estimates," or similar expressions that indicate future events and trends. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, the Company can give no assurance that these expectations will prove to be correct, and the Company's actual results may differ significantly from the results discussed in these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise.
